The data include a plenary poster, one of the highest‑ranked categories selected by the ASBMR committee. Entera plans a single, randomised, double‑blind, placebo‑controlled phase 3 trial involving around 750 postmenopausal women to support a potential New Drug Application. He added: “The effects on trabecular and cortical bone suggest that bone strengthening and fracture resistance may occur rapidly with EB613.” Postmenopausal women are at particular risk due to oestrogen deficiency, which accelerates bone loss in the first decade after menopause. Forteo was approved by the FDA in 2002 for postmenopausal osteoporosis and later for men at high fracture risk and for glucocorticoid‑associated osteoporosis.